​

Barinthus Biotherapeutics (BRNS) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

BRNS Stock Forecast

Barinthus Biotherapeutics (BRNS) stock forecast, based on 3 Wall Street analysts, predicts a 12-month average price target of $3.00, with a high of $3.00 and a low of $3.00. This represents a 215.79% increase from the last price of $0.95.

High: $3 Avg: $3 Low: $3 Last Closed Price: $0.95

BRNS Stock Rating

Barinthus Biotherapeutics stock's rating consensus is Buy, based on 3 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 3 0 3 Strong Sell Sell Hold Buy Strong Buy

BRNS Forecast vs Benchmarks

TypeNameUpside
StockBarinthus Biotherapeutics215.79%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts113
Avg Price Target$3.00$3.00$3.67
Last Closing Price$0.95$0.95$0.95
Upside/Downside215.79%215.79%286.32%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2512---3
Dec, 2413---4
Nov, 24231--6
Oct, 24231--6
Sep, 24231--6
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 13, 2025Yi ChenH.C. Wainwright$3.00$1.15160.87%215.79%
Jun 13, 2024Yi ChenH.C. Wainwright$5.00$1.87167.38%426.32%
Jun 13, 2024Carter GouldBarclays$3.00$1.9057.89%215.79%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 13, 2025H.C. WainwrightBuyBuyhold
Aug 13, 2024Alliance Global PartnersBuyBuyhold
Jun 13, 2024H.C. WainwrightBuyBuyhold
Jun 13, 2024BarclaysOverweightOverweighthold
May 20, 2024Alliance Global PartnersBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-1.96$0.14$-1.92----
Avg Forecast$-1.94$0.26$-2.03$-1.48$-1.44$-1.77$-1.99
High Forecast$-1.94$0.26$-2.27$-1.54$-1.67$-1.77$-1.99
Low Forecast$-1.94$0.26$-1.87$-1.41$-1.20$-1.77$-1.99
Surprise %1.03%-46.15%-5.42%----

Revenue Forecast

$0 $9M $18M $27M $36M $45M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$268.00K$44.70M$805.11K----
Avg Forecast$514.50K$41.35M$810.00K$9.98M$500.00K$738.66K$185.76K
High Forecast$514.50K$41.35M$488.38K$9.98M$500.00K$738.66K$185.76K
Low Forecast$514.50K$41.35M$1.34M$9.98M$500.00K$738.66K$185.76K
Surprise %-47.91%8.10%-0.60%----

Net Income Forecast

$-90M $-70M $-50M $-30M $-10M $10M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-50.87M$5.34M$-73.63M----
Avg Forecast$-74.60M$9.87M$-77.73M$-56.68M$-55.13M$-68.04M$-76.42M
High Forecast$-74.60M$9.87M$-87.31M$-59.15M$-63.97M$-68.04M$-76.42M
Low Forecast$-74.60M$9.87M$-71.84M$-54.22M$-45.88M$-68.04M$-76.42M
Surprise %-31.82%-45.90%-5.28%----

BRNS Forecast FAQ

Is Barinthus Biotherapeutics stock a buy?

Barinthus Biotherapeutics stock has a consensus rating of Buy, based on 3 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Barinthus Biotherapeutics is a favorable investment for most analysts.

What is Barinthus Biotherapeutics's price target?

Barinthus Biotherapeutics's price target, set by 3 Wall Street analysts, averages $3 over the next 12 months. The price target range spans from $3 at the low end to $3 at the high end, suggesting a potential 215.79% change from the previous close price of $0.95.

How does Barinthus Biotherapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Barinthus Biotherapeutics stock forecast shows a 215.79% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Barinthus Biotherapeutics over the past three months?

  • January 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Barinthus Biotherapeutics’s EPS forecast?

Barinthus Biotherapeutics's average annual EPS forecast for its fiscal year ending in December is -1.48 for 2024, a -22.92% decrease from the reported $-1.92 in 2023. The prediction for 2025 is $-1.44, $-1.77 for 2026, and $-1.99 for 2027.

What is Barinthus Biotherapeutics’s revenue forecast?

Barinthus Biotherapeutics's average annual revenue forecast for its fiscal year ending in December is $9.98M for 2024, a 1139.50% increase from the reported $805.11K in 2023. The forecast for 2025 is $500K, $738.66K for 2026, and $185.76K for 2027.

What is Barinthus Biotherapeutics’s net income forecast?

For its fiscal year ending in December, Barinthus Biotherapeutics's average annual net income forecast is $-56.683M for 2024, reflecting a -23.02% decrease from the reported $-73.631M in 2023. The projection for 2025 is $-55.135M, $-68.042M for 2026, and $-76.424M for 2027.